Bionano Genomics to Host Strategy Day on February 2, 2023 in New York City
Bionano Genomics (BNGO) announced its inaugural Strategy Day on February 2, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will showcase presentations from the leadership team and discussions with key opinion leaders in cancer and genetic disorders. A Q&A session will follow, allowing audience interaction. A live webcast will be available for registration through the company's website. Bionano focuses on genome analysis solutions, enhancing research in biology and medicine.
- None.
- None.
SAN DIEGO, Jan. 06, 2023 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (BNGO) today announced that it will host its first-ever Strategy Day on Thursday, February 2nd, 2023, at the Nasdaq MarketSite in New York City, starting at 1:30 PM ET. The event will include presentations from members of the company's leadership team and panel discussions featuring key opinion leaders in basic and clinical research areas including cancer, genetic disorders and cell bioprocessing. Bionano panel members will also participate in a Q&A discussion with the audience.
The event will include a live webcast which will be archived and available for replay after the event. Please visit the "Investors" section of the company website at https://ir.bionanogenomics.com/ to register for the webcast and for additional information on the event.
About Bionano Genomics
Bionano Genomics is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through OGM solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also provides diagnostic testing for patients with clinical presentations consistent with autism spectrum disorder and other neurodevelopmental disabilities. The Company also offers an industry-leading, platform-agnostic software solution, which integrates next-generation sequencing and microarray data designed to provide analysis, visualization, interpretation and reporting of copy number variants, single-nucleotide variants and absence of heterozygosity across the genome in one consolidated view.
For more information, visit www.bionanogenomics.com, www.bionanolaboratories.com or www.biodiscovery.com
CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionanogenomics.com
Investor Relations:
Amy Conrad
Juniper Point
+1 (858) 366-3243
amy@juniper-point.com
FAQ
What is the date and time of Bionano Genomics' first Strategy Day?
Where will Bionano Genomics host its Strategy Day event?
What topics will be discussed at Bionano Genomics' Strategy Day?
Will there be a Q&A session during Bionano Genomics' Strategy Day?